Zydus Lifesciences has successfully secured the Establishment Inspection Report (EIR) and official approval from the USFDA for its oncology injectable manufacturing facility located in SEZ1, Ahmedabad. This approval follows a successful Pre-Approval Inspection (PAI) conducted in late 2025. The clearance specifically validates the company’s new isolator injectable line, marking a significant milestone in enhancing the firm’s specialized manufacturing capabilities for critical oncology treatments.
Successful USFDA Inspection
Zydus Lifesciences has announced a positive outcome from the USFDA regarding its manufacturing site in SEZ1, Ahmedabad. The company received the Establishment Inspection Report (EIR) and the associated approval letter, confirming that the facility meets international quality and safety standards. This development comes after a comprehensive Pre-Approval Inspection (PAI) carried out by federal authorities between November 4th and November 13th, 2025.
Focus on Specialized Manufacturing
The regulatory clearance pertains to the company’s new isolator injectable line dedicated to oncology products. This advanced manufacturing infrastructure is designed to maintain high sterility and precision, which is critical for the production of complex cancer medications. With this approval now in place, Zydus is well-positioned to scale its production capacity and expand its footprint in the oncology therapeutic segment, ensuring consistent supply and operational readiness for the global market.
Source: BSE
